Zoetis ZTS Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| International | $1.15B+2.5% | $1.12B+6.3% | $1.06B-1.4% | $1.07B+8.6% | $985M-5.2% | |
| U.S. | $1.09B-11.8% | $1.24B-6.5% | $1.32B-2.5% | $1.36B+14.6% | $1.18B-5.9% | |
| Gross Profit by Business | ||||||
| International | $815M+7.8% | $756M+4.4% | $724M-4.2% | $756M+9.6% | $690M-1.8% | |
| U.S. | $896M-12.4% | $1.02B-7.0% | $1.1B-4.2% | $1.15B+16.7% | $984M-4.3% | |
| Nonoperating Income (Expense) by Business | ||||||
| International | -$1M-133% | $3M+400% | -$1M— | $0— | $0-100% | |
| U.S. | $0— | $0— | $0— | $0— | $0+100% | |
| Operating expenses by Business | ||||||
| International | $175M-4.4% | $183M+9.6% | $167M-3.5% | $173M+6.1% | $163M-9.4% | |
| U.S. | $199M+3.1% | $193M-4.0% | $201M-7.8% | $218M+6.3% | $205M-3.3% | |
| Income before provision for taxes on income by Business | ||||||
| International | $639M+11.3% | $574M+3.2% | $556M-4.6% | $583M+10.6% | $527M+0.8% | |
| Other business activities | -$141M+11.3% | -$159M-13.6% | -$140M-4.5% | -$134M-0.8% | -$133M+11.9% | |
| U.S. | $697M-16.0% | $830M-7.7% | $899M-3.3% | $930M+19.4% | $779M-4.9% | |
| Gross margin, percentage by Business | ||||||
| International | 70.9%— | —— | 68.6%-2.1pp | 70.7%+0.6pp | 70.1%— | |
| U.S. | 82.2%— | —— | 83.2%-1.5pp | 84.7%+1.5pp | 83.2%+83.1pp | |
| Depreciation and amortization expense by Business | ||||||
| International | $26M0.0% | $26M0.0% | $26M+4.0% | $25M+8.7% | $23M0.0% | |
| Other business activities | $13M0.0% | $13M-7.1% | $14M+7.7% | $13M+18.2% | $11M-21.4% | |
| U.S. | $23M0.0% | $23M-8.0% | $25M+13.6% | $22M-4.3% | $23M+15.0% | |
| Cost of Sales by Business | ||||||
| International | $334M-8.5% | $365M+10.3% | $331M+5.4% | $314M+6.4% | $295M-12.2% | |
| U.S. | $194M-8.9% | $213M-4.1% | $222M+6.7% | $208M+4.5% | $199M-13.1% | |
| Revenue by Product | ||||||
| Animal health diagnostics | $117M+5.4% | $111M+0.9% | $110M0.0% | $110M+5.8% | $104M+4.0% | |
| Anti-infectives | $241M-15.1% | $284M0.0% | $284M+29.7% | $219M-8.0% | $238M-15.3% | |
| Cattle | $392M-5.5% | $415M+4.0% | $399M+24.7% | $320M-6.2% | $341M-14.5% | |
| Contract manufacturing & human health | $23M-23.3% | $30M+30.4% | $23M-32.4% | $34M+13.3% | $30M+42.9% | |
| Dermatology | $349M-18.6% | $429M-9.1% | $472M+1.9% | $463M+22.2% | $379M-10.0% | |
| Dogs and Cats | $1.44B— | —— | $1.59B-7.6% | $1.72B+16.2% | $1.48B— | |
| Fish | $66M-18.5% | $81M+3.8% | $78M+5.4% | $74M+34.5% | $55M-15.4% | |
| Horses | $76M-98.8% | $6.08B+9,112% | $66M-8.3% | $72M+12.5% | $64M-98.9% | |
| Other Non Pharmaceuticals | $66M-5.7% | $70M+9.4% | $64M+1.6% | $63M-11.3% | $71M+9.2% | |
| Other pharmaceutical | $158M-16.0% | $188M+5.6% | $178M+3.5% | $172M+8.9% | $158M-12.2% | |
| Pain and sedation | $203M-2.9% | $209M+2.5% | $204M-6.0% | $217M+4.8% | $207M-4.6% | |
| Parasiticides | $586M+8.1% | $542M-3.9% | $564M-16.2% | $673M+17.7% | $572M+10.2% | |
| Poultry | $118M+0.9% | $117M+10.4% | $106M+2.9% | $103M-2.8% | $106M-9.4% | |
| Sheep and other | $21M+16.7% | $18M-41.9% | $31M+40.9% | $22M+10.0% | $20M+17.6% | |
| Swine | $123M-1.6% | $125M+12.6% | $111M-6.7% | $119M+13.3% | $105M-18.0% | |
| Vaccines | $519M+1.4% | $512M+3.2% | $496M-1.6% | $504M+14.8% | $439M-5.0% | |
| Revenue by Geography | ||||||
| Australia | $89M+6.0% | $84M-3.4% | $87M+4.8% | $83M+5.1% | $79M-1.3% | |
| Brazil | $90M-19.6% | $112M+12.0% | $100M+7.5% | $93M+14.8% | $81M-28.3% | |
| Canada | $73M-8.8% | $80M+14.3% | $70M-4.1% | $73M+4.3% | $70M-6.7% | |
| Chile | $38M-5.0% | $40M+37.9% | $29M-19.4% | $36M+2.9% | $35M+16.7% | |
| China | $63M+26.0% | $50M+11.1% | $45M-37.5% | $72M+30.9% | $55M-15.4% | |
| France | $37M-28.8% | $52M+30.0% | $40M+21.2% | $33M-15.4% | $39M-13.3% | |
| Germany | $59M-9.2% | $65M+4.8% | $62M+6.9% | $58M+5.5% | $55M-6.8% | |
| Italy | $39M+11.4% | $35M0.0% | $35M-7.9% | $38M+26.7% | $30M-11.8% | |
| Japan | $35M-10.3% | $39M+14.7% | $34M-24.4% | $45M+40.6% | $32M-15.8% | |
| Mexico | $48M+9.1% | $44M+7.3% | $41M+7.9% | $38M+8.6% | $35M-12.5% | |
| Other developed markets | $169M-7.1% | $182M+11.0% | $164M+1.2% | $162M+21.8% | $133M-11.9% | |
| Other emerging markets | $291M+37.3% | $212M-7.0% | $228M+1.3% | $225M-5.5% | $238M+22.1% | |
| Spain | $40M+8.1% | $37M-2.6% | $38M+2.7% | $37M+27.6% | $29M-3.3% | |
| Total geographical area | $2.24B-5.0% | $2.36B-0.8% | $2.38B-2.0% | $2.43B+11.9% | $2.17B-5.6% | |
| United Kingdom | $78M-12.4% | $89M+8.5% | $82M+6.5% | $77M+4.1% | $74M-11.9% | |
| United States | $1.09B-11.8% | $1.24B-6.5% | $1.32B-2.5% | $1.36B+14.6% | $1.18B-5.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Zoetis break its business down?
- Zoetis (ZTS) reports revenue by business across 2 parts — International and U.S.. Each is extracted from the segment footnotes and tracked over time.
- Where does Zoetis's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Zoetis's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
